Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9

Replimune

Replimune

REPL

0.00

Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ: REPL) with a Neutral and raises the price target from $6 to $9.